Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko
Expectations For US Biosimilars ‘May Have Been Excessive’
Executive Summary
In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.
You may also be interested in...
Amgen Gets US Infliximab Nod
Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.
US Trastuzumab Competition Heats Up
Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.
FDA Reviews Samsung Bioepis’ Bevacizumab
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.